Association Between Geriatric Nutritional Risk Index and Gemcitabine Plus Nab-Paclitaxel Continuation in Elderly Patients With Pancreatic Cancer.

BACKGROUND/AIM: This retrospective study evaluated the impact of Geriatric Nutritional Risk Index (GNRI) group on time to treatment failure (TTF) in 63 older adults (≥65 years) with unresectable pancreatic cancer receiving gemcitabine plus nab-paclitaxel.

PATIENTS AND

METHODS

Receiver operating characteristic analysis established a GNRI cutoff of 94.7, which was used to classify patients into high and low GNRI groups.

RESULTS

The median TTF was significantly longer for the high GNRI group (116.5 days) than the low GNRI group (91 days, p=0.026). Furthermore, multivariate analysis revealed that GNRI ≥94.7 (hazard ratio=0.55, 95% confidence interval=0.31-0.95) and prior chemotherapy (hazard ratio=2.01, 95% confidence interval=1.06-3.78) were independent factors significantly influencing TTF.

CONCLUSION

Baseline GNRI is a predictor of treatment continuation. Therefore, early nutritional assessment using the GNRI may help optimize treatment strategies and supportive care in older patients with pancreatic cancer.